Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma SA disclosure: Novo Nordisk A/S filed Schedule 13G/A (Amendment No. 4) reporting 0 shares beneficially owned representing 0.00% of Innate Pharma's ordinary shares. The amendment is signed by Karsten Munk Knudsen, Chief Financial Officer, on 06/22/2026.
Innate Pharma S.A. reported the results of its 2026 Annual General Meeting held in Marseille on May 21, 2026. All resolutions were voted, with a total of 94 votes cast out of 34,872,293 shares representing 34,921,313 voting rights, corresponding to a 37,136% quorum.
The detailed resolutions, voting results, related documents and an AGM recording will be provided in the 2026 Annual General Meeting section of the company’s website. Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies for cancer, with collaborations including AstraZeneca and Sanofi.
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, filed a Form 6-K to share that its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York from June 2–4, 2026.
The company highlights its pipeline of potential first- or best-in-class antibody-based therapies, including IPH4502 for solid tumors, lacutamab for T-cell lymphomas, and monalizumab, which is being developed with AstraZeneca for non-small cell lung cancer. Innate also notes broader collaborations with partners such as Sanofi and AstraZeneca and its listings on Euronext Paris and Nasdaq.
Innate Pharma reported its latest business update and financial position alongside full-year 2025 results. The company is preparing the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab in cutaneous T‑cell lymphomas in H2 2026, contingent on non-dilutive financing such as pharma partnering and royalty deals now under negotiation.
IPH4502, a Nectin-4 ADC, reached its maximum tolerated dose in Phase 1 with preliminary anti-tumor activity and a favorable safety profile, while AstraZeneca-led PACIFIC‑9 and the MATISSE Phase 2 study for IPH5201 continue to advance in non-small cell lung cancer. Cash, cash equivalents and financial assets totaled €25.4 million as of March 31, 2026, providing an expected cash runway until the end of Q3 2026, and Q1 2026 revenue was €2.6 million, primarily from AstraZeneca and Sanofi collaborations.
Innate Pharma S.A. reports its capital and voting structure as of April 16, 2026. The company has 93,934,210 shares outstanding, made up of 93,921,863 ordinary shares, 4,766 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights is 93,921,863, while exercisable voting rights, excluding treasury shares with suspended rights, total 93,903,288.
Innate Pharma S.A. filed a Form 6-K to share a press release announcing a conference call and webcast to discuss its business progress for the first quarter of 2026. The call will take place on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT.
Management participants will include the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Head of Investor Relations, and Chief Financial Officer. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
The release also briefly describes Innate Pharma as a global, clinical-stage biotechnology company focused on cancer immunotherapies, highlighting key programs such as IPH4502, lacutamab and monalizumab, and noting collaborations with partners including AstraZeneca and Sanofi.
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, reported that its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026. The company highlights a portfolio of next-generation antibody therapeutics, including IPH4502, lacutamab and monalizumab, developed alone or in collaboration with partners such as AstraZeneca and Sanofi. Headquartered in Marseille with a U.S. office in Rockville, Innate is listed on Euronext Paris and Nasdaq and directs readers to its French and U.S. regulatory filings for detailed risk factors.
Innate Pharma reported encouraging interim results from the Phase 2 MATISSE trial of IPH5201 in resectable non-small cell lung cancer. The study combines IPH5201, a first-in-class anti-CD39 antibody, with durvalumab and platinum-based chemotherapy in previously untreated, resectable NSCLC.
In a pre-planned interim analysis of 40 patients, the combination showed higher pathological complete response rates than a benchmark of durvalumab plus chemotherapy alone. Pathological complete response reached 35.7% in tumors with PD-L1 ≥1% and 50% in tumors with PD-L1 ≥50%.
On the basis of these data, MATISSE continues enrolling patients whose tumors express PD-L1 ≥1%. The interim results will be presented in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026, highlighting IPH5201’s potential role in enhancing anti-tumor immune responses in early-stage lung cancer.
Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.
The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.
Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.
The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.
Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.
The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.
Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.
The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.